GOSS (GOSS) Stock Analysis
Verdict: AVOID
Phase 3 seralutinib is the sole value driver, but a 2025 cash burn of $171M against $37M in liquidity makes a dilutive 'death spiral' likely.
Investment score: 38/100
Avoid GOSS due to imminent insolvency risk and extreme cash burn that necessitates heavy dilution before Phase 3 data matures.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| KLRS | -2.01 | 1.49 | 0.00 | -1.08 | — | 0.00 |
| ALDX | -3.39 | 2.22 | 0.00 | -1.74 | — | 0.00 |
| PTHS | -0.66 | 2.52 | 0.63 | -0.76 | — | -1.86 |
| FBIO | 0.71 | 0.53 | 1.37 | -0.76 | — | 1.93 |
| BMEA | -1.39 | 4.75 | 0.00 | -0.99 | — | 0.00 |